Nanjing Leads Biolabs Co Ltd

9887.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$69.55

−HK$1.65 · -2.32%

Aug 24, 11:59 AM HKT

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: Xiaoqiang Kang
Listed since: Jul 25, 2025
Employees: 244

Market position

Day range

Current HK$69.55

HK$68.70HK$73.45

52-week range

Current HK$69.55

HK$44.72HK$97.50

Open: HK$73.35
Previous close: HK$71.20
Volume: 742.8K; 0.48× average
Average volume: 1.54M; Average daily volume
Market cap: 13.83B HKD
Beta: 1.37; Market reference 1
50-day average: HK$58.9504; +17.98% above average
200-day average: HK$62.4708; +11.33% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 7.04B CNY
P/E (TTM): -141.56×
P/B (TTM): 8.11×
P/S (TTM): 60.58×
EV / EBITDA: -35.36×
Earnings yield: -2.95%
Free cash flow yield: -2.07%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 100.00%
Operating margin: -28.06%
Net margin: -38.19%
Return on equity: -18.58%
Return on assets: -13.20%
Return on invested capital: -14.00%

Financial health

Debt / equity: 0.22×
Current ratio: 3.37×
Altman Z-score: 13.04
Piotroski F-score: 4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

197.2M CNY+1921.59%

Operating income

−216.42M CNY-443.22%

Net income

−235.21M CNY-435.82%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022
Revenue	197.2M CNY	—	9.75M CNY	—
Cost of goods sold	—	—	3.5M CNY	17.78M CNY
Gross profit	197.2M CNY	—	6.25M CNY	−17.78M CNY
Research and development	321.62M CNY	27.06M CNY	254.03M CNY	172.69M CNY
Selling, general, and administrative	92.01M CNY	12.78M CNY	41.87M CNY	23.06M CNY
Operating expenses	413.62M CNY	39.84M CNY	295.9M CNY	195.76M CNY
Interest income	28.8M CNY	8.29M CNY	6.56M CNY	2.39M CNY
Interest expense	7M CNY	5.76M CNY	1.4M CNY	303.32K CNY
Depreciation and amortization	17.39M CNY	2.95M CNY	21.72M CNY	17.78M CNY
Operating income	−216.42M CNY	−39.84M CNY	−289.65M CNY	−213.54M CNY
Net income	−235.21M CNY	−43.9M CNY	−398.61M CNY	−286.77M CNY